
HUTCHMED (HKEX:0013), (NASDAQ:HCM) is a global biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company is known for its robust pipeline of innovative drug candidates, several of which are in advanced stages of clinical trials with the aim of addressing unmet medical needs across various regions. HUTCHMED is committed to advancing healthcare by developing highly effective treatments, with a focus on bringing novel solutions to patients worldwide. The company actively collaborates with academic, industrial, and healthcare partners to expand its reach and impact in the healthcare sector.